HomeImmunovia AB

Immunovia AB

IMMray™ PanCan-d Serum Biomarker Test Detects Early Pancreatic Cancer With 96% Accuracy: Published in Journal of Clinical Oncology

8/15/18: Mats Grahn, CEO Immunovia said: "We are delighted to see the publication of this study in JCO, which confirms that IMMray™ PanCan-d can detect pancreatic cancer in the earliest stages with an accuracy as high as 96%, in two completely different patient cohorts collected independently on different continents. "